newsfilter
← Earnings
Earnings Releases·

Rapid Micro Biosystems — Third Quarter 2026 Earnings Summary

  • Total revenue increased 21.6% year-over-year to $9.5 million, driven by a 24.9% rise in product revenue and a 14.9% increase in service revenue, while total gross margin expanded 16.3 percentage points to a record 25.2%.
  • The Company withdrew its full year 2026 guidance and delayed its Form 10-Q filing following the signing of a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany.
  • Net loss narrowed slightly to $11.3 million ($0.23 per share) from $11.5 million in the prior year quarter, with non-GAAP adjusted EBITDA loss improving to $7.9 million.
  • Strategic progress included seven new Growth Direct system placements and a strong partnership with Merck KGaA, though the acquisition remains subject to closing conditions and potential shareholder litigation.
  • The company reported cash, cash equivalents, and short-term investments of approximately $7 million alongside $19.2 million in notes payable, net, as of September 30, 2026.
Company
RAPID MICRO BIOSYSTEMS INC
Sector
Healthcare
Industry
Medical Devices